FDA Awards Priority Review Voucher to Sponsor of Rare Pediatric Disease Product GAMIFANT

Summary

The FDA has issued a priority review voucher to Novimmune S.A., the manufacturer of GAMIFANT (emapalumab-lzsg) Injection, a rare pediatric disease product, following a review of the product's eligibility under the FD&C Act and FDASIA.